<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270109" xml:lang="en" article-type="case-study"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40161320</article-id><article-id pub-id-type="pmc">PMC11953733</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70109</article-id><article-id pub-id-type="publisher-id">DEO270109</article-id><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Oxaliplatin&#x02010;induced portal hypertension manifesting as portosystemic shunt: A case report and review of sinusoidal obstruction syndrome in gastric cancer</article-title><alt-title alt-title-type="left-running-head">ICHIMARU <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270109-cr-0001" contrib-type="author"><name><surname>Ichimaru</surname><given-names>Toshimitsu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0958-9873</contrib-id><xref rid="deo270109-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270109-cr-0002" contrib-type="author" corresp="yes"><name><surname>Sakamoto</surname><given-names>Takamitsu</given-names></name><xref rid="deo270109-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>takamitsusakamoto@gmail.com</email></address></contrib><contrib id="deo270109-cr-0003" contrib-type="author"><name><surname>Amagai</surname><given-names>Teruyoshi</given-names></name><xref rid="deo270109-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="deo270109-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Fukuoka Tokushukai General Hospital</institution>
<city>Fukuoka</city>
<country country="JP">Japan</country>
</aff><aff id="deo270109-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Engineering</named-content>
<named-content content-type="organisation-division">Faculty of Health Care Sciences</named-content>
<institution>Jikei University of Health Care Sciences</institution>
<city>Osaka</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Takamistu Sakamoto, Fukuoka Tokushukai General Hospital, 816&#x02010;0864,4&#x02010;5 Sugu Kita, Kasuga, Fukuoka, Japan.<break/> Email: <email>takamitsusakamoto@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="9">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70109</elocation-id><history>
<date date-type="rev-recd"><day>17</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>21</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>21</day><month>3</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70109.pdf"/><abstract><title>Abstract</title><p>A 77&#x02010;year&#x02010;old woman with stage IVB gastric adenocarcinoma (cT4N2M1) received 10 cycles of S&#x02010;1, oxaliplatin, and nivolumab combination chemotherapy. Imaging and biopsy confirmed a complete response. However, thrombocytopenia, mild splenomegaly, and elevated liver enzymes developed following oxaliplatin administration. After the tenth cycle, a contrast&#x02010;enhanced computed tomography scan revealed a portosystemic shunt. Oxaliplatin was discontinued, but the shunt persisted after 1 year. Balloon&#x02010;occluded retrograde transvenous obliteration was successfully performed, resulting in the resolution of the shunt. This case highlights the potential for oxaliplatin&#x02010;induced portal hypertension requiring close monitoring.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270109-kwd-0001">advanced gastric cancer</kwd><kwd id="deo270109-kwd-0002">oxaliplatin</kwd><kwd id="deo270109-kwd-0003">portal hypertension</kwd><kwd id="deo270109-kwd-0004">portosystemic shunt</kwd><kwd id="deo270109-kwd-0005">sinusoidal obstructive syndrome</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="4"/><word-count count="1521"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:07.04.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270109-sec-0010"><title>INTRODUCTION</title><p>Gastric cancer remains a significant clinical challenge, with some cases diagnosed at an advanced stage. Oxaliplatin, a third&#x02010;generation platinum&#x02010;based chemotherapeutic agent, is frequently used in combination with S&#x02010;1 and nivolumab for unresectable gastric cancer. Sinusoidal obstruction syndrome (SOS), a known adverse effect of oxaliplatin, can manifest as portal hypertension. This case report describes a patient with oxaliplatin&#x02010;associated SOS presenting with a portosystemic shunt successfully treated with prophylactic balloon&#x02010;occluded retrograde transvenous obliteration (BRTO).</p><sec id="deo270109-sec-0020"><title>Case presentation</title><p>A 77&#x02010;year&#x02010;old woman presented to Fukuoka Tokushukai General Hospital with advanced gastric cancer. Endoscopy revealed a neoplasm in the posterior wall of the upper gastric body and fundus, confirmed histologically as HER2&#x02010;negative adenocarcinoma (Figure&#x000a0;<xref rid="deo270109-fig-0001" ref-type="fig">1</xref>). Contrast&#x02010;enhanced computed tomography scan (CE&#x02010;CT) and positron emission tomography (PET)&#x02010;CT staging revealed stage IVB disease (T4N3M1; Figure&#x000a0;<xref rid="deo270109-fig-0001" ref-type="fig">1</xref>). She received 10 cycles of S&#x02010;1, oxaliplatin (SOX), and nivolumab for 8 months.</p><fig position="float" fig-type="FIGURE" id="deo270109-fig-0001"><label>FIGURE 1</label><caption><p>Positron emission tomography&#x02010;computed tomography (PET&#x02010;CT) shows abnormal accumulation in gastric artery lymph nodes and periaortic lymph nodes. Stomach biopsy shows adenocarcinoma (Group 5), HER2 negative. Gene testing (FISH) was negative. CE&#x02010;CT, contrast&#x02010;enhanced computed tomography.</p></caption><graphic xlink:href="DEO2-5-e70109-g002" position="anchor" id="jats-graphic-1"/></fig><p>During SOX therapy, thrombocytopenia developed (Figure&#x000a0;<xref rid="deo270109-fig-0002" ref-type="fig">2</xref>). Post&#x02010;chemotherapy CE&#x02010;CT demonstrated a complete response. However, subsequent gastroscopy revealed a complete response to chemotherapy, but also the presence of a variceal&#x02010;like vessel, confirmed by CE&#x02010;CT (Figure&#x000a0;<xref rid="deo270109-fig-0003" ref-type="fig">3</xref>), which showed mild splenomegaly and enlargement of the portosystemic shunt. Oxaliplatin was discontinued after 8 months.</p><fig position="float" fig-type="FIGURE" id="deo270109-fig-0002"><label>FIGURE 2</label><caption><p>Course of treatment and changes in platelet count, Fibrosis&#x02010;4 index, and APRI. Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; BRTO, balloon&#x02010;occluded transfemoral obliteration; CE&#x02010;CT, contrast medium&#x02010;enhanced computed tomography.</p></caption><graphic xlink:href="DEO2-5-e70109-g003" position="anchor" id="jats-graphic-3"/></fig><fig position="float" fig-type="FIGURE" id="deo270109-fig-0003"><label>FIGURE 3</label><caption><p>Endoscopic findings suspicious for the variceal&#x02010;like vessel (arrow), and complete response to chemotherapy. Contrast medium&#x02010;enhanced computed tomography (CE&#x02010;CT) shows a complete response to chemotherapy and the formation of a portosystemic shunt (circle) and suspected mild enlargement of the shunt 1 year after oxaliplatin discontinuation.</p></caption><graphic xlink:href="DEO2-5-e70109-g001" position="anchor" id="jats-graphic-5"/></fig><p>While the incidence of varices rupture is relatively low, it remains a clinically significant concern.</p><p>Although asymptomatic, she presented with hyperammonemia at 84&#x000a0;(reference range: 12&#x02013;66&#x000a0;&#x000b5;g/dL). Persistent thrombocytopenia, enlargement of portosystemic shunt, and hyperammonemia prompted prophylactic BRTO (Figure&#x000a0;<xref rid="deo270109-fig-0004" ref-type="fig">4</xref>) after a duration of 20 months from the initiation of chemotherapy. The postoperative course was uneventful, and no adverse event occurred, S&#x02010;1 and nivolumab therapy continued for 2 years. Postoperative ammonia data improved to 37&#x000a0;&#x000b5;g/dL, but platelet counts did not increase.</p><fig position="float" fig-type="FIGURE" id="deo270109-fig-0004"><label>FIGURE 4</label><caption><p>The venogram of balloon&#x02010;occluded transfemoral obliteration (BRTO) procedure. Post&#x02010;BRTO contrast&#x02010;enhanced computed tomography (CE&#x02010;CT) reveals occlusion of the portosystemic shunt (circle).</p></caption><graphic xlink:href="DEO2-5-e70109-g004" position="anchor" id="jats-graphic-7"/></fig></sec></sec><sec id="deo270109-sec-0030"><title>DISCUSSION</title><p>This case report describes a 77&#x02010;year&#x02010;old woman with stage IVB gastric adenocarcinoma who developed portal hypertension after only 10 cycles of oxaliplatin&#x02010;based chemotherapy (SOX and nivolumab), a significantly shorter timeframe than the previously reported median of 50.4 months.<xref rid="deo270109-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> This rapid onset of portosystemic shunt, coupled with their persistence even after oxaliplatin discontinuation, suggests a potentially aggressive form of oxaliplatin&#x02010;induced portal hypertension and irreversible damage. Furthermore, this case contributes to the limited literature on oxaliplatin&#x02010;induced portosystemic shunt, specifically in gastric cancer patients, highlighting a critical area needing further investigation. The successful resolution of the shunt using BRTO adds to the clinical experience with this intervention in this context. Finally, the case underscores the inadequacy of current diagnostic criteria for chemotherapy&#x02010;induced SOS, particularly in gastric cancer, emphasizing the need for refined diagnostic tools and a greater understanding of the long&#x02010;term consequences of oxaliplatin&#x02010;induced portal hypertension. To summarize SOS symptomatology, serology, and images, painful hepatomegaly, ascites, weight gain&#x000a0;(&#x0003e;5% of pre&#x02010;chemotherapy), serum bilirubin&#x000a0;(&#x0003e;2&#x000a0;mg/dL), transaminases (&#x0003e;2 times normal), and no specific findings in CT and MRI.<xref rid="deo270109-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Oxaliplatin, a cornerstone of first&#x02010;line chemotherapy regimens for advanced gastric cancer chemotherapy, is associated with various adverse effects, including neurotoxicity, gastrointestinal disturbances, and hematologic toxicities. However, a potentially serious and often under&#x02010;recognized long&#x02010;term complication is SOS, which can manifest as non&#x02010;cirrhotic portal hypertension.<xref rid="deo270109-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The incidence of SOS following oxaliplatin&#x02010;based chemotherapy ranges widely, from 19% to 52%,<xref rid="deo270109-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> and its clinical presentation can be variable.</p><p>While oxaliplatin&#x02010;induced hepatic sinusoidal injury is well&#x02010;documented,<xref rid="deo270109-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> the precise pathological mechanisms linking oxaliplatin exposure to non&#x02010;cirrhotic portal hypertension remain incomplete.<xref rid="deo270109-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> While some studies report a median time to varices manifestation of 50.4 months after oxaliplatin initiation,<xref rid="deo270109-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> our patient exhibited a more rapid onset of thrombocytopenia and portosystemic shunt, developing within 10 cycles of SOX chemotherapy.</p><p>The patient's presentation&#x02014;thrombocytopenia, mild splenomegaly, and portosystemic shunt developing temporally after oxaliplatin administration&#x02014;strongly suggests oxaliplatin&#x02010;induced SOS as the underlying etiology. The absence of other known risk factors for portal hypertension further supports this causal link. Although elevated liver enzymes are sometimes associated with SOS, the presence of portal hypertension, manifested by splenomegaly and varices, is a more reliable diagnostic indicator than isolated mild elevations in liver function tests. Furthermore, elevated aminotransferase to platelet ratio index (and Fibrosis&#x02010;4 scores, also associated with splenomegaly, can provide additional diagnostic support.<xref rid="deo270109-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>Importantly, in our patient, portal hypertension appeared irreversible, with persistent thrombocytopenia and varices even after oxaliplatin discontinuation. This observation aligns with previous reports indicating that oxaliplatin&#x02010;induced SOS can lead to persistent portal hypertension. The commonly used Jones criteria for SOS diagnosis are primarily applicable to post&#x02010;hematopoietic stem cell transplantation settings<xref rid="deo270109-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> and may not accurately reflect chemotherapy&#x02010;induced SOS. This highlights the need for the development of specific diagnostic criteria for chemotherapy&#x02010;related SOS, particularly in the context of gastric cancer, given the paucity of data in this specific patient population.<xref rid="deo270109-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>This case underscores the critical importance of close monitoring for clinical signs of portal hypertension, including platelet counts, splenomegaly, aminotransferase to platelet ratio index, Fibrosis&#x02010;4, and endoscopic findings, in patients receiving oxaliplatin&#x02010;based chemotherapy for gastric cancer.<xref rid="deo270109-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Early detection allows for timely prophylactic interventions, such as BRTO in this instance, potentially preventing serious complications.<xref rid="deo270109-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> The successful BRTO procedure in our patient further emphasizes the value of proactive management. Follow&#x02010;up is also necessary after BRTO with adequate concern for rupture hemorrhage of esophagogastric varices.</p><p>However, this case report, while informative, is limited by its inherent nature as a single case study.</p><p>Larger prospective studies with comprehensive pathological correlation are crucial to definitively establish the causal relationship between oxaliplatin and the development of gastric varices in gastric cancer patients and to refine diagnostic criteria for chemotherapy&#x02010;induced SOS. This case highlights the need for increased clinician awareness of this rare but potentially serious complication of oxaliplatin therapy in gastric cancer.</p></sec><sec sec-type="COI-statement" id="deo270109-sec-0040"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270109-sec-0050"><title>ETHICS STATEMENT</title><p>This case report did not include any analysis of human or animal subjects by any of the authors.</p></sec><sec id="deo270109-sec-0060"><title>PATIENT CONSENT STATEMENT</title><p>The patient provided informed consent for this case report.</p></sec></body><back><ref-list id="deo270109-bibl-0001"><title>REFERENCES</title><ref id="deo270109-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270109-cite-0001">
<string-name>
<surname>Huang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin&#x02010;based chemotherapy in patients with colorectal cancer</article-title>. <source>Endoscopy</source>
<year>2020</year>; <volume>52</volume>: <fpage>727</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">32380558</pub-id>
</mixed-citation></ref><ref id="deo270109-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270109-cite-0002">
<string-name>
<surname>Mohty</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Malard</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Alaskar</surname>
<given-names>AS</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno&#x02010;occlusive disease in adult patients: A refined classification from the European Society for Blood and Marrow Transplantation (EBMT)</article-title>. <source>Bone Marrow Transplant</source>
<year>2023</year>; <volume>58</volume>: <fpage>749</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">37095231</pub-id>
</mixed-citation></ref><ref id="deo270109-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270109-cite-0003">
<string-name>
<surname>Ye</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tu</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Case report: Oxaliplatin&#x02010;induced idiopathic non&#x02010;cirrhotic portal hypertension: A case report and literature review</article-title>. <source>Front Med</source>
<year>2023</year>; <volume>10</volume>: <elocation-id>1285064</elocation-id>.</mixed-citation></ref><ref id="deo270109-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270109-cite-0004">
<string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>DZ</given-names>
</string-name>, <string-name>
<surname>Qian</surname>
<given-names>BX</given-names>
</string-name>. <article-title>Isolated gastric variceal bleeding related to non&#x02010;cirrhotic portal hypertension following oxaliplatin&#x02010;based chemotherapy: A case report</article-title>. <source>World J Gastroenterol</source>
<year>2022</year>; <volume>28</volume>: <fpage>3524</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">36158260</pub-id>
</mixed-citation></ref><ref id="deo270109-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270109-cite-0005">
<string-name>
<surname>Slade</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Alattar</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Fogelman</surname>
<given-names>DR</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Portal hypertension associated with oxaliplatin administration: Clinical manifestations of hepatic sinusoidal injury</article-title>. <source>Clin Colorectal Cancer</source>
<year>2009</year>; <volume>8</volume>: <fpage>225</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">19822514</pub-id>
</mixed-citation></ref><ref id="deo270109-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270109-cite-0006">
<string-name>
<surname>Nagahama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ueno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Terada</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Oxaliplatin&#x02010;induced sinusoidal obstructive syndrome: A comparative study on clinical and pathological findings</article-title>. <source>Kanzo</source>
<year>2022</year>; <volume>63</volume>: <fpage>372</fpage>&#x02013;<lpage>80</lpage>.</mixed-citation></ref><ref id="deo270109-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270109-cite-0007">
<string-name>
<surname>Cairo</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Cooke</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Lazarus</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Chao</surname>
<given-names>N</given-names>
</string-name>. <article-title>Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation</article-title>. <source>Br J Haematol</source>
<year>2020</year>; <volume>190</volume>: <fpage>822</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">32133623</pub-id>
</mixed-citation></ref><ref id="deo270109-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270109-cite-0008">
<string-name>
<surname>Ogata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gushima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maruoka</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic> [<article-title>A case of portal hypertension after 5&#x02010;fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy]</article-title>. <source>Jpn J Gastroenterol</source>
<year>2013</year>; <volume>110</volume>: <fpage>2119</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref></ref-list></back></article>